Search filters

Filters
Clear All

Phase

  • 1
  • 2
  • 4
  • 2
  • 9
  • 18
  • 4
  • 8
  • 1
  • 9

Found 18 Prostate Cancer trials

A listing of Prostate Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Study Evaluating the Safety   and tolerability of AMG 757 and determine the maximum tolerated dose
18 years - 99 years
Male
Interventional
The purpose of this study is to obtain initial information on the safety and tolerability (effects good or bad) of a short-term intravenous (IV) infusion of AMG 757 for the treatment of neuroendocrine prostate cancer (a certain type of prostate cancer). This study will also look at what doses of …
 Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
18 years - 99 years
Male
Observational
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
18 years or above
Male
Phase 3
Interventional
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in …
 Mild Hypofractionation using Proton Therapy or IMRT for Low- and Intermediate-Risk Prostate Cancer
99 years or below
All genders
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of low or intermediate risk of prostate cancer presenting for definitive radiation treatment with either proton radiotherapy or IMRT. We propose to employ a hypofractionated strategy …
18 years - 99 years
Male
Interventional
This study involves research and is conducted to determine the safety, tolerability (how 6 your body reacts to the drug) and effectiveness of a study drug called REGN5678 which 7 will be given alone first and then be given in combination with cemiplimab.
 Study of Regn4336 administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer
18 years - 99 years
Male
Interventional
This research study is designed to learn more about the safety and effectiveness of REGN4336 alone or in combination with cemiplimab given to individuals who have been diagnosed with Prostate Cancer.
 SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
18 years - 99 years
Male
Phase 3
Interventional
This is a research study for those with metastatic castration-resistant prostate cancer (mCRPC) that has progressed following treatment with prior therapy and cannot receive or refuse to receive chemotherapy. The purpose of this research study is to learn about the safety and effectiveness of 177Lu PNT2002, an investigational agent being …
 Study of JNJ-75229414  a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
18 years - 99 years
Male
Phase 1
Interventional
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
 Study to Evaluate the Safety  Tolerability  and   Preliminary Efficacy of XmAb 20717 Alone or in Combination with Chemotherapy or Targeted Therapies in  Selected Subjects with Metastatic Castration-Resistant Prostate Cancer
18 years - 99 years
All genders
The primary purposes of this research study are to determine the safety and tolerability of XmAb20717 by itself and in combination with other anticancer therapies. Subjects are being asked to take part in this research study because they have metastatic castration resistant prostate cancer (mCRPC), a prostate cancer that has …
1 - 10 of 18